Loading
Led the ibrutinib trials that turned CLL from a chemotherapy disease into one treated with pills.
John Byrd (University of Cincinnati; formerly Ohio State) led the pivotal phase 1b/2 and RESONATE trials of ibrutinib in chronic lymphocytic leukaemia, the results that made BTK inhibition the standard of care and displaced chemoimmunotherapy, and the ELEVATE-RR head-to-head trial showing acalabrutinib is better tolerated. His laboratory helped develop acalabrutinib and continues work on resistance and AML therapeutics.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tags cll, btk.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
Shares Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors and the tag cll.
Shares RESONATE, Beat AML Master Trial, Chronic lymphocytic leukaemia, Small-molecule kinase inhibitors.
Shares Small-molecule kinase inhibitors and the tag targeted-therapy.
Shares RESONATE, Chronic lymphocytic leukaemia.